Company Number: 14541651

Analysis Date: 2025-07-20 14:38 UTC

Financial Health Assessment for BIEDRONCA LTD

---

1. Financial Health Score: D

Explanation:
BIEDRONCA LTD demonstrates an extremely modest financial base with very limited net assets (£83) and negligible operational scale (no employees, micro-account category). While there is a positive working capital position, the very low equity and accruals nearly offset assets, indicating fragile financial health typical of an embryonic or start-up stage business. The score reflects caution due to minimal capital buffer and limited financial depth.

---

2. Key Vital Signs

Metric	Value (£)	Interpretation
Current Assets	2,404	Small cash or equivalents and receivables; indicates limited short-term resources.
Current Liabilities	252	Low short-term obligations; manageable but must be monitored closely.
Net Current Assets (Working Capital)	2,152	Positive, suggesting the company can cover its short-term debts — a "healthy cash flow symptom."
Accruals and Deferred Income	2,069	Significant relative to assets; could indicate income received in advance or expenses yet to be incurred.
Net Assets (Equity)	83	Very low equity base; signals minimal shareholder investment or very early stage company.
Employees	0	No staff employed; likely a sole-operated or non-operational company at this stage.

---

3. Diagnosis

The financial "vitals" of BIEDRONCA LTD show a business in its infancy, with a very thin capital structure and minimal financial resources. The positive net current assets indicate the company can meet short-term obligations, a good sign of liquidity, but the very low net assets and the significant accruals relative to total assets are "symptoms of financial fragility."

The lack of employees and the micro-entity filing status suggest the company is either just starting, or in a dormant or preparatory phase without significant trading activity. The accruals and deferred income almost equal the net current assets, which could mask a more delicate financial position if those deferred items reverse.

Overall, the company shows early-stage "health," but the financial "pulse" is weak, with limited resilience to shocks or unexpected expenses. The sole director and controlling shareholder structure imply tight control but also concentration risk.

---

4. Recommendations

• Boost Equity Capital: Consider injecting additional funds to strengthen the equity base, improving the company's financial "immune system" against shocks.
• Clarify Accruals/Deferred Income: Review the nature of the £2,069 accruals to ensure these liabilities or income deferrals are valid and manageable.
• Develop Operational Activity: To move beyond the start-up "incubation" phase, focus on generating revenue streams and potentially hiring staff to support growth.
• Monitor Cash Flow Closely: Maintain healthy cash flow management to avoid liquidity stress despite currently positive working capital.
• Prepare for Scaling: As the company grows, ensure timely filing of accounts and returns to avoid compliance symptoms that could complicate financial health.
• Consider External Advice: Engage with financial or business advisors to create a growth plan and risk management strategy, given the fragile capital position.

---